Simulations Plus’ New Software Version (NASDAQ:SLP)

Simulations Plus, Inc (NASDAQ:SLP) has announced that they have released the new version of GastroPlus state of the art software which is being used by many pharmaceutical research scientists for simulation of oral absorption, intravenous dosing, pharmacokinetics, and pharmacodynamics. Simulations Plus is a premier developer of groundbreaking drug discovery and development software, which is licensed to and used in the conduct of drug research by pharmaceutical, biotechnology, and drug delivery companies worldwide. This new version of GastroPlus known as Version 6.1 incorporates both new types of analysis as well as numerous user convenience features suggested by the worldwide user community.

@@AdsenseLeft@@ Announcing about the release of the new version of GastroPlus, team leader for Simulations Plus’ Simulation Technologies, Dr. Lukacova said that the simulation capability has been expanded in the latest version to include dosing to the oral cavity via lingual (top of the tongue), sublingual (under the tongue), and buccal (inside the cheek) routes of administration. They have also added a long list of convenience features that help both new and experienced users to avoid common mistakes, to provide flexible units for various input data, and to extend the output options in both graphics and text formats.

Dr. Lukacova also said that now that they have launched the version 6.1, they will have to work hard on Version 7.0 which will be released early next year. Additionally, the upcoming version will include a comprehensive drug-drug interaction capability as well as the ocular and nasal/pulmonary administration routes.